Arrowhead Pharmaceuticals (NASDAQ:ARWR) Trading Down 8% - What's Next?

Key Points

• Shares fell 8% to about $58.50 on Friday, trading as low as $58.25 with volume of 1,057,595 shares (down ~66% versus the average session) after a prior close of $63.60.
• Mixed quarterly results: Arrowhead missed EPS ($0.22 vs. $0.60 consensus) but beat revenue ($264.0M vs. $225.7M), and analysts have been raising targets — consensus rating is a "Moderate Buy" with an average price target of $81.67.
• Insider selling and ownership profile: insiders sold roughly 485,836 shares (~$32.1M) in the past three months, institutions own 62.61% of the stock, and the company has a market cap of $8.1B with a P/E of 37.8.

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Get Free Report) shares traded down 8% during trading on Friday . The stock traded as low as $58.25 and last traded at $58.50. 1,057,595 shares were traded during trading, a decline of 66% from the average session volume of 3,079,045 shares. The stock had previously closed at $63.60.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on ARWR shares. B. Riley Financial increased their price target on Arrowhead Pharmaceuticals from $61.00 to $101.00 and gave the stock a "buy" rating in a research report on Thursday, January 22nd. Chardan Capital boosted their price target on Arrowhead Pharmaceuticals from $60.00 to $80.00 and gave the company a "buy" rating in a research note on Wednesday, January 7th. Weiss Ratings raised shares of Arrowhead Pharmaceuticals from a "sell (d-)" rating to a "hold (c-)" rating in a research report on Friday, February 6th. Piper Sandler reissued an "overweight" rating and issued a $110.00 target price (up from $100.00) on shares of Arrowhead Pharmaceuticals in a report on Tuesday, January 13th. Finally, The Goldman Sachs Group boosted their target price on shares of Arrowhead Pharmaceuticals from $50.00 to $85.00 and gave the company a "neutral" rating in a research report on Wednesday, January 7th. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $81.67.

Arrowhead Pharmaceuticals Stock Performance

The company has a debt-to-equity ratio of 0.29, a current ratio of 3.38 and a quick ratio of 3.38. The stock has a market cap of $8.10 billion, a P/E ratio of 37.78 and a beta of 1.23. The stock has a 50-day simple moving average of $65.67 and a 200-day simple moving average of $49.59.

Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) last posted its earnings results on Thursday, February 5th. The biotechnology company reported $0.22 EPS for the quarter, missing analysts' consensus estimates of $0.60 by ($0.38). The company had revenue of $264.03 million during the quarter, compared to the consensus estimate of $225.66 million. Arrowhead Pharmaceuticals had a return on equity of 35.64% and a net margin of 18.54%.The firm's revenue was up 10461.3% compared to the same quarter last year. During the same period last year, the company posted ($1.39) EPS. Research analysts forecast that Arrowhead Pharmaceuticals, Inc. will post -2.42 earnings per share for the current year.

Insider Transactions at Arrowhead Pharmaceuticals

In other Arrowhead Pharmaceuticals news, Director Adeoye Y. Olukotun sold 10,000 shares of the business's stock in a transaction on Friday, December 19th. The shares were sold at an average price of $67.66, for a total transaction of $676,600.00. Following the sale, the director owned 33,600 shares of the company's stock, valued at approximately $2,273,376. The trade was a 22.94% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, COO Patrick O'brien sold 49,493 shares of the company's stock in a transaction on Monday, January 5th. The stock was sold at an average price of $63.11, for a total transaction of $3,123,503.23. Following the transaction, the chief operating officer owned 474,908 shares of the company's stock, valued at $29,971,443.88. This trade represents a 9.44% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 485,836 shares of company stock valued at $32,117,910. Corporate insiders own 3.60% of the company's stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. Tsfg LLC acquired a new stake in Arrowhead Pharmaceuticals during the 4th quarter worth approximately $25,000. iSAM Funds UK Ltd acquired a new position in shares of Arrowhead Pharmaceuticals during the third quarter worth $29,000. First Horizon Corp bought a new stake in shares of Arrowhead Pharmaceuticals in the fourth quarter worth $32,000. Virtus Advisers LLC acquired a new stake in Arrowhead Pharmaceuticals in the second quarter valued at $34,000. Finally, Salomon & Ludwin LLC bought a new position in Arrowhead Pharmaceuticals during the 3rd quarter worth $34,000. Institutional investors and hedge funds own 62.61% of the company's stock.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company's approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company's pipeline includes multiple candidates in various stages of development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.